Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

Keith Lindor, T. M. Therneau, R. A. Jorgensen, M. Malinchoc, E. R. Dickson

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background and Aims: Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model. Methods: One hundred eighty patients were randomized to receive either 13-15 mg · kg-1 · day-1 UDCA (n = 89) or placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, or crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover. Results: At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients. Conclusions: UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis.

Original languageEnglish (US)
Pages (from-to)1515-1518
Number of pages4
JournalGastroenterology
Volume110
Issue number5
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Survival
Placebos
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. / Lindor, Keith; Therneau, T. M.; Jorgensen, R. A.; Malinchoc, M.; Dickson, E. R.

In: Gastroenterology, Vol. 110, No. 5, 1996, p. 1515-1518.

Research output: Contribution to journalArticle

Lindor, Keith ; Therneau, T. M. ; Jorgensen, R. A. ; Malinchoc, M. ; Dickson, E. R. / Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. In: Gastroenterology. 1996 ; Vol. 110, No. 5. pp. 1515-1518.
@article{49cea5170dbc4cbf8d1d3128b341b91f,
title = "Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis",
abstract = "Background and Aims: Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model. Methods: One hundred eighty patients were randomized to receive either 13-15 mg · kg-1 · day-1 UDCA (n = 89) or placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, or crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover. Results: At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients. Conclusions: UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis.",
author = "Keith Lindor and Therneau, {T. M.} and Jorgensen, {R. A.} and M. Malinchoc and Dickson, {E. R.}",
year = "1996",
doi = "10.1053/gast.1996.v110.pm8613058",
language = "English (US)",
volume = "110",
pages = "1515--1518",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

AU - Lindor, Keith

AU - Therneau, T. M.

AU - Jorgensen, R. A.

AU - Malinchoc, M.

AU - Dickson, E. R.

PY - 1996

Y1 - 1996

N2 - Background and Aims: Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model. Methods: One hundred eighty patients were randomized to receive either 13-15 mg · kg-1 · day-1 UDCA (n = 89) or placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, or crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover. Results: At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients. Conclusions: UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis.

AB - Background and Aims: Ursodeoxycholic acid (UDCA) has been shown to be a safe and effective treatment for patients with primary biliary cirrhosis; however, its effect on patient survival is less certain. To study this issue, the survival of patients receiving long-term UDCA treatment was compared with that of a control group, adjusting for their risk scores based on the Mayo model. Methods: One hundred eighty patients were randomized to receive either 13-15 mg · kg-1 · day-1 UDCA (n = 89) or placebo (n = 91). After the study closure, the patients originally receiving placebo were switched to active drug, and prospective follow-up was continued for 3 years. Patients were censored at the time of transplantation, voluntary withdrawal, or crossover of the placebo group (efficacy analysis). The survival of the two groups was adjusted for risk scores at the time of entry to the study. A secondary analysis was an intent-to-treat analysis, whereby patients were followed up regardless of their voluntary withdrawal or crossover. Results: At the time of analysis, the patients receiving placebo had a significantly increased risk of death and/or requiring transplantation (relative risk, 2.6; P = 0.04) compared with the UDCA-treated patients. Conclusions: UDCA should be considered as a safe, effective, and life-extending treatment for patients with primary biliary cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=0029911629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029911629&partnerID=8YFLogxK

U2 - 10.1053/gast.1996.v110.pm8613058

DO - 10.1053/gast.1996.v110.pm8613058

M3 - Article

C2 - 8613058

AN - SCOPUS:0029911629

VL - 110

SP - 1515

EP - 1518

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -